Weekly Digest – July 2025 Weekly Digest – July 2025 17 July 2025: ENHERTU plus Pertuzumab granted breakthrough therapy designation in the U.S. as first-line therapy for patients with HER2 positive metastatic breast cancer ENHERTU (Trastuzumab deruxtecan) plus Pertuzumab has […]
Weekly Digest – July 2025 Weekly Digest – July 2025 17 July 2025: FDA advisors spurn GSK’s Blenrep comeback dreams on safety, trial concerns The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted against GSK’s efforts to reintroduce its multiple myeloma […]
Weekly Digest – July 2025 Weekly Digest – July 2025 16 July 2025: Nature Medicine published Phase 1 results of Innovent Biologics’ anti-CLDN18.2 ADC (IBI343) in patients with advanced gastric/gastroesophageal junction adenocarcinoma Phase 1 results of Innovent Biologics’ anti-CLDN18.2 ADC, […]
Weekly Digest – July 2025 Weekly Digest – July 2025 14 July 2025: Oncomatryx Biopharma awarded prestigious EIC accelerator funding to advance groundbreaking ADCs Oncomatryx Biopharma has secured €2.5 million in grant funding and a €10 million equity investment from […]
Weekly Digest – July 2025 Weekly Digest – July 2025 14 July 2025: Defence’s Accum technology with ADC and radiopharmaceutical programs target cancer Defence Therapeutics is advancing its Accum-based ADC and radiopharmaceutical programs, showing superior intracellular delivery and cytotoxicity in […]
Weekly Digest – July 2025 Weekly Digest – July 2025 15 July 2025: Sino Biopharm buys Merck’s PD-1xVEGF bispecific partner LaNova for up to $951M Sino Biopharm is acquiring LaNova Medicines for up to $951 million, consolidating its earlier minority […]
